Company Overview

SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of cancer immunotherapies and hematology-oncology therapeutics. The company operates primarily in the biotechnology and oncology drug development industries, with an emphasis on therapies targeting difficult-to-treat cancers and hematologic malignancies. SELLAS is publicly traded on Nasdaq under the ticker SLS and has concentrated its efforts on advancing clinical-stage assets through regulatory development and strategic partnerships.

The company’s primary value drivers are its lead product candidates, including galinpepimut-S (GPS), a Wilms Tumor 1 (WT1)-targeting cancer immunotherapy, and SLS009 (tambiciclib), a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor under development for hematologic cancers. SELLAS has historically focused on leveraging immunotherapeutic approaches alongside precision oncology strategies for patients with limited treatment options. Originally formed through a combination involving Galena Biopharma’s oncology assets and later restructured under the SELLAS brand, the company evolved into a clinical-stage oncology developer with a pipeline centered on immuno-oncology and targeted therapeutics.

Business Operations

SELLAS generates value primarily through the clinical development and potential future commercialization of its oncology pipeline. Its operations are organized around the advancement of proprietary therapeutic candidates, particularly GPS and SLS009, through clinical trials, regulatory interactions, intellectual property management, and strategic licensing arrangements. The company does not currently generate significant commercial product revenue and instead relies on financing activities, licensing arrangements, and collaborations to fund operations. Clinical development activities have included studies in acute myeloid leukemia (AML), mesothelioma, ovarian cancer, and other oncology indications.

The company maintains operations primarily in the United States, while conducting or supporting multinational clinical trial activities through contract research organizations, academic cancer centers, and international clinical partners. SELLAS controls intellectual property associated with its therapeutic platforms and has pursued partnerships related to manufacturing, clinical development, and commercialization support. The company has also maintained relationships with leading cancer treatment institutions and cooperative study groups involved in oncology research and trial enrollment.

Strategic Position & Investments

SELLAS has positioned itself as a focused oncology biotechnology company targeting areas of high unmet medical need, particularly hematologic malignancies and refractory cancers. A major strategic initiative has been the continued advancement of GPS in AML through late-stage clinical development, including maintenance therapy settings where relapse prevention remains a major challenge. Another significant strategic focus is the development of SLS009, which has been investigated for AML and other blood cancers due to its CDK9 inhibition profile and potential combination utility with existing therapies.

The company’s investment priorities have centered on expanding clinical evidence, securing regulatory pathways, strengthening intellectual property protections, and pursuing strategic collaborations that may accelerate development or commercialization opportunities. SELLAS has also explored biomarker-driven oncology strategies and precision medicine applications. Its portfolio reflects an emphasis on differentiated therapeutic mechanisms rather than broad diversified operations, which distinguishes the company from larger multi-platform biotechnology firms.

Geographic Footprint

SELLAS is headquartered in New York, United States, and its operational footprint is primarily concentrated in North America. However, the company’s clinical activities and development collaborations extend into additional regions through international trial sites and research relationships. The company has engaged with investigators, hospitals, and service providers across multiple jurisdictions to support oncology studies and regulatory development activities.

The company’s market and operational exposure includes the United States, parts of Europe, and selected international clinical research markets. While SELLAS does not maintain the extensive global commercial infrastructure of larger pharmaceutical companies, its development strategy relies on international clinical participation and global regulatory engagement to support future commercialization potential and partnership opportunities.

Leadership & Governance

SELLAS is led by an executive team with backgrounds in biotechnology, pharmaceuticals, oncology development, finance, and corporate strategy. The company’s leadership has emphasized disciplined capital allocation, advancement of late-stage oncology assets, and the pursuit of strategic partnerships designed to maximize shareholder value while progressing clinical programs. Corporate governance is overseen by a board of directors with experience across life sciences, investment management, and healthcare operations.

Key executives include:

• Angelos Stergiou, MD, ScD h.c. – President and Chief Executive Officer
• Dimitris Voliotis – Chief Financial Officer
• Dror Harats, MD – Senior Vice President, Head of Development
• Nickolas Tsiolas – Vice President, Legal Affairs and Corporate Secretary

Public disclosures, including SEC filings, company investor materials, and clinical trial records consistently identify the company’s strategic focus as the advancement of oncology therapeutics targeting hematologic and solid tumor indications. Information regarding certain partnership structures and future commercialization plans remains limited in publicly available disclosures.